Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants - Full Text View - ClinicalTrials.gov

SPG302 trial set to begin in Australia
SPG302 trial set to begin in Australia | MND Australia

Second half of phase one study in Australia beginning . . . hoping to increase synapses in motor system.